Cargando…

Pharmaceutical cost control in primary care: opinion and contributions by healthcare professionals

BACKGROUND: Strategies adopted by health administrations and directed towards drug cost control in primary care (PC) can, according to earlier studies, generate tension between health administrators and healthcare professionals. This study collects and analyzes the opinions of general practitioners...

Descripción completa

Detalles Bibliográficos
Autores principales: Prados-Torres, Alexandra, Calderón-Larrañaga, Amaia, Sicras-Mainar, Antoni, March-Llull, Sebastià, Oliván-Blázquez, Bárbara
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2784461/
https://www.ncbi.nlm.nih.gov/pubmed/19922620
http://dx.doi.org/10.1186/1472-6963-9-209
_version_ 1782174750384062464
author Prados-Torres, Alexandra
Calderón-Larrañaga, Amaia
Sicras-Mainar, Antoni
March-Llull, Sebastià
Oliván-Blázquez, Bárbara
author_facet Prados-Torres, Alexandra
Calderón-Larrañaga, Amaia
Sicras-Mainar, Antoni
March-Llull, Sebastià
Oliván-Blázquez, Bárbara
author_sort Prados-Torres, Alexandra
collection PubMed
description BACKGROUND: Strategies adopted by health administrations and directed towards drug cost control in primary care (PC) can, according to earlier studies, generate tension between health administrators and healthcare professionals. This study collects and analyzes the opinions of general practitioners (GPs) regarding current cost control measures as well as their proposals for improving the effectiveness of these measures. METHODS: A qualitative exploratory study was carried out using 11 focus groups composed of GPs from the Spanish regions of Aragon, Catalonia and the Balearic Islands. A semi-structured guide was applied in obtaining the GPs' opinions. The transcripts of the dialogues were analyzed by two investigators who independently considered categorical and thematic content. The results were supervised by other members of the team, with overall responsibility assigned to the team leader. RESULTS: GPs are conscious of their public responsibility with respect to pharmaceutical cost, but highlight the need to spread responsibility for cost control among the different actors of the health system. They insist on implementing measures to improve the quality of prescriptions, avoiding mere quantitative evaluations of prescription costs. They also suggest moving towards the self-management of the pharmaceutical budget by each health centre itself, as a means to design personalized incentives to improve their outcomes. These proposals need to be considered by the health administration in order to pre-empt the feelings of injustice, impotence, frustration and lack of motivation that currently exist among GPs as a result of the implemented measures. CONCLUSION: Future investigations should be oriented toward strategies that involve GPs in the planning and management of drug cost control mechanisms. The proposals in this study may be considered by the health administration as a means to move toward the rational use of drugs while avoiding concerns about injustice and feelings of impotence on the part of the GPs, which can lead to lack of interest in and disaffection with the current measures.
format Text
id pubmed-2784461
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27844612009-11-27 Pharmaceutical cost control in primary care: opinion and contributions by healthcare professionals Prados-Torres, Alexandra Calderón-Larrañaga, Amaia Sicras-Mainar, Antoni March-Llull, Sebastià Oliván-Blázquez, Bárbara BMC Health Serv Res Research article BACKGROUND: Strategies adopted by health administrations and directed towards drug cost control in primary care (PC) can, according to earlier studies, generate tension between health administrators and healthcare professionals. This study collects and analyzes the opinions of general practitioners (GPs) regarding current cost control measures as well as their proposals for improving the effectiveness of these measures. METHODS: A qualitative exploratory study was carried out using 11 focus groups composed of GPs from the Spanish regions of Aragon, Catalonia and the Balearic Islands. A semi-structured guide was applied in obtaining the GPs' opinions. The transcripts of the dialogues were analyzed by two investigators who independently considered categorical and thematic content. The results were supervised by other members of the team, with overall responsibility assigned to the team leader. RESULTS: GPs are conscious of their public responsibility with respect to pharmaceutical cost, but highlight the need to spread responsibility for cost control among the different actors of the health system. They insist on implementing measures to improve the quality of prescriptions, avoiding mere quantitative evaluations of prescription costs. They also suggest moving towards the self-management of the pharmaceutical budget by each health centre itself, as a means to design personalized incentives to improve their outcomes. These proposals need to be considered by the health administration in order to pre-empt the feelings of injustice, impotence, frustration and lack of motivation that currently exist among GPs as a result of the implemented measures. CONCLUSION: Future investigations should be oriented toward strategies that involve GPs in the planning and management of drug cost control mechanisms. The proposals in this study may be considered by the health administration as a means to move toward the rational use of drugs while avoiding concerns about injustice and feelings of impotence on the part of the GPs, which can lead to lack of interest in and disaffection with the current measures. BioMed Central 2009-11-18 /pmc/articles/PMC2784461/ /pubmed/19922620 http://dx.doi.org/10.1186/1472-6963-9-209 Text en Copyright ©2009 Prados-Torres et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research article
Prados-Torres, Alexandra
Calderón-Larrañaga, Amaia
Sicras-Mainar, Antoni
March-Llull, Sebastià
Oliván-Blázquez, Bárbara
Pharmaceutical cost control in primary care: opinion and contributions by healthcare professionals
title Pharmaceutical cost control in primary care: opinion and contributions by healthcare professionals
title_full Pharmaceutical cost control in primary care: opinion and contributions by healthcare professionals
title_fullStr Pharmaceutical cost control in primary care: opinion and contributions by healthcare professionals
title_full_unstemmed Pharmaceutical cost control in primary care: opinion and contributions by healthcare professionals
title_short Pharmaceutical cost control in primary care: opinion and contributions by healthcare professionals
title_sort pharmaceutical cost control in primary care: opinion and contributions by healthcare professionals
topic Research article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2784461/
https://www.ncbi.nlm.nih.gov/pubmed/19922620
http://dx.doi.org/10.1186/1472-6963-9-209
work_keys_str_mv AT pradostorresalexandra pharmaceuticalcostcontrolinprimarycareopinionandcontributionsbyhealthcareprofessionals
AT calderonlarranagaamaia pharmaceuticalcostcontrolinprimarycareopinionandcontributionsbyhealthcareprofessionals
AT sicrasmainarantoni pharmaceuticalcostcontrolinprimarycareopinionandcontributionsbyhealthcareprofessionals
AT marchllullsebastia pharmaceuticalcostcontrolinprimarycareopinionandcontributionsbyhealthcareprofessionals
AT olivanblazquezbarbara pharmaceuticalcostcontrolinprimarycareopinionandcontributionsbyhealthcareprofessionals